Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a single-site, double-blinded, randomized clinical trial designed to elucidate mechanism(s) of action for symptomatic benefits observed in Parkinson's disease (PD)
Description: Arterial arrival time (AAT) measured using pseudo Continuous Arterial Spin Labeling (pCASL) magnetic resonance imaging (MRI) will be used to monitor changes in global perfusion.
Measure: Change in cerebral blood flow (CBF) perfusion Time: baselineDescription: Arterial arrival time (AAT) measured using pseudo Continuous Arterial Spin Labeling (pCASL) magnetic resonance imaging (MRI) will be used to monitor changes in global perfusion.
Measure: Change in cerebral blood flow (CBF) perfusion Time: end of treatment (week 12)Description: AAT measured using pCASL MRI after a hypercapnic challenge will be used to monitor changes in cerebrovascular reactivity
Measure: Change in cerebrovascular Reactivity Time: baselineDescription: AAT measured using pCASL MRI after a hypercapnic challenge will be used to monitor changes in cerebrovascular reactivity
Measure: Change in cerebrovascular Reactivity Time: end of treatment (week 12)Description: Resting-state magnetic resonance imaging (rs-MRI) will be used to monitor changes in functional connectivity
Measure: Change in functional connectivity Time: baseline and end of treatment (week 12)Description: Transcranial Doppler sonography (TCD), a non-invasive ultrasound, will be used to monitor changes in cerebral blood flow velocity (cm/s) in response to a hypercapnic challenge.
Measure: Change in cerebral haemodynamics Time: baseline and end of treatment (week 12)Description: Arterial arrival time (AAT) measured using pseudo Continuous Arterial Spin Labeling (pCASL) magnetic resonance imaging (MRI) will be used to monitor changes in global perfusion.
Measure: Durability of change of cerebral blood flow (CBF) perfusion Time: baseline and the post-treatment follow-up (week 17)Description: AAT measured using pCASL MRI after a hypercapnic challenge will be used to monitor changes in cerebrovascular reactivity
Measure: Durability of change of cerebrovascular Reactivity Time: baseline and the post-treatment follow-up (week 17)Description: Resting-state magnetic resonance imaging (rs-MRI) will be used to monitor changes in functional connectivity
Measure: Durability of change of functional connectivity Time: baseline and the post-treatment follow-up (week 17)Description: Used to follow the longitudinal course of symptoms of Parkinson's disease - Each parkinsonian sign or symptom is rated on a 5-point Likert-type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total UPDRS score is 199, indicating the worst possible disability from PD
Measure: Change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Time: baseline, end of treatment (week 12), and the post-treatment follow-up (week 17)Description: To determine fall risk and measure the progress of balance, sit to stand and walking (ranging from ≤10 seconds as normal to 30 seconds as high fall risk).
Measure: Change in the Timed Up and Go Test Time: baseline, end of treatment (week 12) and the post-treatment follow-up (week 17)Description: Cognitive screening test - range from zero to 30, with a score of 26 and higher generally considered normal.
Measure: Change in the Montreal Cognitive Assessment Time: baseline, end of treatment (week 12) and the post-treatment follow-up (week 17)Description: Scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease - 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The Non-Motor Symptom Scale measures the severity and frequency of non-motor symptoms across nine dimensions - the total score significantly increased with disease severity and duration meaning that the number of individual non-motor symptoms reported by our patients increases as the disease progresses. Score range 0 - 360.
Measure: Change in the Non-Motor Symptom Scale Time: Change between the baseline and end of treatment (week 12) measure.Description: Scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease - 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The Non-Motor Symptom Scale measures the severity and frequency of non-motor symptoms across nine dimensions - the total score significantly increased with disease severity and duration meaning that the number of individual non-motor symptoms reported by our patients increases as the disease progresses. Score range 0 - 360.
Measure: Change in the Non-Motor Symptom Scale Time: Change between the baseline and the post-treatment follow-up (week 17) measure.Description: A self-report measure of depression in older adults - Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Measure: Change in the Geriatric Depression Scale Time: baseline, end of treatment (week 12) and the post-treatment follow-up (week 17)Description: Anxiety assessment - The PAS is a 12-item observer or patient-rated scale with three subscales, for persistent, episodic anxiety and avoidance behavior - There is a maximum total score of 48. Higher scores indicate great experiences of anxiety.
Measure: Change in the Parkinson's Anxiety Scale Time: baseline, end of treatment (week 12) and the post-treatment follow-up (week 17)Description: A self-administered questionnaire to assess the daytime sleepiness - The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.
Measure: Change in the Epworth Sleepiness Scale Time: baseline, end of treatment (week 12) and the post-treatment follow-up (week 17)Description: A tool to help manage chronic illness - The responses to the 13 items on the FACIT fatigue questionnaire are each measured on a 4-point Likert scale. Thus, the total score ranges from 0 to 52. High scores represent less fatigue
Measure: Change in the Functional Assessment of Chronic Illness Therapy - Fatigue Time: baseline, end of treatment (week 12) and the post-treatment follow-up (week 17)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports